Minocycline in acne system therapy
- 作者: Samtsov A.V.1
-
隶属关系:
- S. M. Kirov Military Medical Academy
- 期: 卷 96, 编号 1 (2020)
- 页面: 67-71
- 栏目: DRUG TREATMENT IN DERMATOVENEROLOGY
- URL: https://ogarev-online.ru/0042-4609/article/view/117032
- DOI: https://doi.org/10.25208/vdv1105-2020-96-1-67-71
- ID: 117032
如何引用文章
全文:
详细
Systemic antibiotics in combination with topical retinoids and benzoyl peroxide are first-line drugs for the treatment of moderate to severe acne. The systemic antibiotic Minocycline has a wide spectrum of action against gram + and gram-organisms, including strains resistant to penicillins and cephalosporins. A pronounced bacteriostatic effect is achieved by a high level of lipophilicity, rapid penetration through the lipid layer of bacteria and intensive accumulation in the sebaceous glands. Minolexin® is a highly effective and safe medication for the treatment of moderate to severe acne and can be recommended for practical use in outpatient practice.
作者简介
Aleksey Samtsov
S. M. Kirov Military Medical Academy
编辑信件的主要联系方式.
Email: avsamtsov@mail.ru
Dr. Sci. (Med.)., Prof., Head of the Department of Skin and Sexually Transmitted Diseases
俄罗斯联邦, Akademika Lebedeva str., 6, Saint Petersburg, 194044参考
- Zaenglein А., Pathy А., Schlosser В. et al. Guidelines of care for the management of acne vulgaris. J Am AcadDermatol. 2016; 74: 945—973.
- Straight Ch., Lee H., Liu G., Kirby J. Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guide line recommend ations and opportunities for cost-savings. J Am Acad Dermatol. 2015; 72: 822—827.
- Garrido-Mesa N., Zarzuelo A., Galves J. Minocycline far beyond an antibiotic. Br J Dermatol. 2013; 109: 337—352.
- Gollnick H., Dreno B. Pathophysiology and management of acne. 2015; 29 (Suppl. 4), 3—11.
- Strauss J., Krowchuk D., Leyden J. et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651—663.
- Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013; 17: 114—122.
- Leyden J.J., Del Rosso J.Q. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol 2011; 4: 40—47.
- Torok H.M. Extended-release formulation of minocycline in the treatment of moderate-to-severe acne vulgaris in patients over the age of 12 years. J Clin Aesthet Dermatol. 2013; 6: 19—22.
- Jung G.W., Tse J.E., Guiha I., Rao J. Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. J Cutan Med Surg. 2013; 17: 114—22.
- Thiboutot D., Dreno B., Abanmi A. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2018; 78: 21—23.
- Stewart D., Torok H., Weiss J., Plott R. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis. 2006; 78 (4Suppl): 11—20.
- Torok H.M. Extended-release Formulation of Minocycline in the Treatment of Moderate-to-severe Acne Vulgaris in Patients over the Age of 12 Years. J Clin Aesthet Dermatol. 2013 Jul; 6: 19—22.
- Ochsendorf F. Systemic antibiotic therapy of acnevulgaris. J. Dtsch. Dermatol. Ges. 2006; 4: 828—41.
- Leyden J.J., Del Rosso J.Q. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J. Clin. Aesthet. Dermatol. 2011; 4: 40—7.
- Snarskaya E.S. Antibacterial therapy of vulgar acne. Vestn Dermatol. 2019; 95: 58—67.
补充文件
